Compare Johnson & Johnson (JNJ) vs Primo Brands Corporation Class A Common Stock (PRMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Primo Brands Corporation Class A Common Stock — how do they compare? Johnson & Johnson trades at $257.6 (market cap $611.90B), while Primo Brands Corporation Class A Common Stock trades at $18.76 (market cap $6.80B). The key difference: Johnson & Johnson is far larger — about 90× Primo Brands Corporation Class A Common Stock's market cap, and Primo Brands Corporation Class A Common Stock pays the higher dividend (2.56%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Primo Brands Corporation Class A Common Stock for 0 Days on average.
| JNJ | PRMB | |
|---|---|---|
Market Cap | $611.90B | $6.80B |
Volume | 9,651,904 | 3,695,669 |
Sector | Health | Consumer Staples |
52-Week High | $278.43 | $25.39 |
52-Week Low | $186.00 | $14.46 |
Typical Hold Time | 129 Days | 0 Days |
Enterprise Value | $640.18B | $12.13B |
Dividend Yield | 2.11% | 2.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $248.61, down 5.73% over 24 hours, with a bullish technical signal supported by moving averages. The company maintains strong profitability with 67.91% gross margins and 21.48% net income margin, though valuation ratios appear elevated with a P/E of 38.59. Recent earnings show consistent beats except for Q4 2025, with Q3 2026 EPS of $2.59 exceeding expectations. Analyst consensus remains positive with a $282.53 price target, representing 13.6% upside potential from current levels.
JNJ's diversified healthcare portfolio and robust dividend history provide stability, while innovation in pharmaceuticals and medical technology drives growth. Key risks include patent expirations, regulatory challenges, and increasing debt levels. The stock offers defensive characteristics with upside potential from pipeline developments, though current valuation requires careful monitoring of execution against growth expectations.
PRMB trades at $18.9, down 1.46% on the day, with a neutral technical signal and key support/resistance clustered around $19. The company reported Q2 2026 EPS of $0.37, beating expectations, and shows improving revenue and net income trends for 2026. Recent news highlights expansion with a new factory opening and strong premium water sales growth, supporting a positive analyst consensus.
The outlook is positive, driven by sales momentum and capacity expansion, but risks include thin net margins and high P/E ratio. With 80% of analysts rating it Buy and a consensus price target of $28.50, the stock offers significant upside potential if execution continues, though margin pressure remains a key watchpoint.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Primo Brands Corporation Class A Common Stock
Primo Brands Corporation is a branded beverage company that produces and distributes packaged and purified water, water dispensers, and filtration equipment across North America, under brands including Poland Spring, Pure Life, Arrowhead, and Primo Water.
Read more on PRMB →
